The DOI matches its Crossref record; 102 of the 104 references it cites were found in a registry or an index.
Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias
Open accessAbstract
Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias Stuart J Thomas, George T GrossbergDepartment of Neurology and Psychiatry, Saint Louis University School of Medicine, St. Louis, MO, USAAbstract: Memantine is an uncompetitive N-methyl-D-aspartate receptor antagonist with moderate affinity. Its mechanism of action is neuroprotective and potentially therapeutic in several neuropsychiatric diseases. It has been approved by the FDA for the treatment of moderate to severe Alzheimer’s disease (AD) either as a monotherapy or in combination with cholinesterase inhibitors. This review covers key studies of memantine’s safety and efficacy in treating moderate to severe AD. It also covers current research into other dementias including but not exclusively mild AD and vascular dementia. Other studies on the efficacy of memantine for other neuropsychiatric diseases are discussed. Memantine is a safe and effective drug that merits further research on several topics. Clinicians should be aware of new studies and potential uses of memantine because of its safety and efficacy.Keywords: memantine, Alzheimer’s disease, dementia
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients taking memantine experience adverse effects like fatigue, pain, confusion, urinary incontinence, urinary tract infection, peripheral edema, etc. [35].”
From Indian Medicinal Herbs and Formulations for Alzheimer’s Disease, from Traditional Knowledge to Scientific Assessment (2020) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Bonfoco, E., Krainc, D., Ankarcrona, M., Nicotera, P., & Lipton, S. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7162 · Cited by 1,958
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond
Lipton, S. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1958 · Cited by 909
Chen, H., Pellegrini, J. W., Aggarwal, S., Lei, S., Warach, S. J., Jensen, F., & Lipton, S. A. (1992) · Journal of Neuroscience · doi:10.1523/jneurosci.12-11-04427.1992 · Cited by 628
β-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage
Koh, J., Yang, L. L., & Cotman, C. W. (1990) · Brain Research · doi:10.1016/0006-8993(90)91355-k · Cited by 617
Orgogozo, J.-M., Rigaud, A.-S., Stöffler, A., Möbius, H.-J., & Forette, F. (2002) · Stroke · doi:10.1161/01.str.0000020094.08790.49 · Cited by 539
Kavirajan, H., & Schneider, L. S. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70195-3 · Cited by 497
Post Stroke Pain: Identification, Assessment, and Therapy
Harrison, R. A., & Field, T. S. (2015) · Cerebrovascular Diseases · doi:10.1159/000375397 · Cited by 434
A Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.153 · Cited by 387
Research works printed but not linked: 1
- [97]Grossberg GT Manes F Allegri R A multinational, randomized, double-blind, placebo-controlled, parallel-group trial of memantine extended-release capsule (28 mg, once daily) in patients with moderate to severe Alzheimer’s disease. [poster] 133rd Annual Meeting of the American Neurological Association September 21–24, 2008 Salt Lake City, UT, USA Clinical Interventions in Aging is an international, peer-reviewed journal focusing on evidence-based reports on the value or lack thereof of treatments intended to prevent or delay the onset of maladaptive correlates of aging in human beings This journal is indexed on PubMed Central, MedLine, the American Chemical Society’s ‘Chemical Abstracts Service’ (CAS), Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.
Cited by
Sorted by citations
Drug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420
O'Brien, J. T., Holmes, C., Jones, M. S., Jones, R. W., Livingston, G., McKeith, I. G., Mittler, P. J., Passmore, P., Ritchie, C. W., Robinson, L. A., et al. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116680924 · Cited by 361
Neurotherapeutic applications of nanoparticles in Alzheimer’s disease
Sahni, J. K., Doggui, S., Ali, J., Baboota, S., Dao, L., & Ramassamy, C. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.033 · Cited by 219
Combination Drug Therapy for the Management of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217
Neuroprotective effects of theanine and its preventive effects on cognitive dysfunction
Kakuda, T. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.03.010 · Cited by 124
Memantine Enhances Recovery From Stroke
López-Valdés, H. E., Clarkson, A. N., Ao, Y., Charles, A. C., Carmichael, S. T., Sofroniew, M. V., & Brennan, K. C. (2014) · Stroke · doi:10.1161/strokeaha.113.004476 · Cited by 124
Advances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases
Salman, M. M., Al-Obaidi, Z. M. J., Kitchen, P., Loreto, A., Bill, R. M., & Wade‐Martins, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094688 · Cited by 121
Mehla, J., Gupta, P., Pahuja, M., Diwan, D., & Diksha, D. (2020) · Brain Sciences · doi:10.3390/brainsci10120964 · Cited by 108
Roles of glutamate signaling in preclinical and/or mechanistic models of depression
Tokita, K., Yamaji, T., & Hashimoto, K. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.016 · Cited by 104
IRSp53/BAIAP2 in dendritic spine development, NMDA receptor regulation, and psychiatric disorders
Kang, J., Park, H., & Kim, E. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.06.019 · Cited by 100
Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions
Miculas, D. C., Negru, P. A., Bungau, S. G., Behl, T., Hassan, S. S. U., & Tit, D. M. (2022) · Cells · doi:10.3390/cells12010131 · Cited by 96
Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease: Comparison with Memantine
Hemmati, F., Dargahi, L., Nasoohi, S., Omidbakhsh, R., Mohamed, Z., Chik, Z., Naidu, M. K., & Ahmadiani, A. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.06.016 · Cited by 95
Torres‐Altoro, M. I., Mathur, B. N., Drerup, J. M., Thomas, R. E., Lovinger, D. M., O'Callaghan, J. P., & Bibb, J. A. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07428.x · Cited by 94
Larsson, V., Aarsland, D., Ballard, C. G., Minthon, L., & Londos, E. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2506 · Cited by 93
Benarroch, E. E. (2011) · Neurology · doi:10.1212/wnl.0b013e31821b7cc9 · Cited by 90
Alzheimer’s disease and its treatment–yesterday, today, and tomorrow
Kim, A. Y., Jerdi, S. A., MacDonald, R., & Triggle, C. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399121 · Cited by 99
Contributions by the Brain Renin-Angiotensin System to Memory, Cognition, and Alzheimer’s Disease
Wright, J. W., & Harding, J. W. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181035 · Cited by 88
Friend, Foe or Both? Immune Activity in Alzheimer’s Disease
Frost, G. R., Jonas, L. A., & Li, Y. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00337 · Cited by 88
Albiston, A. L., Diwakarla, S., Fernando, R. N., Mountford, S. J., Yeatman, H. R., Morgan, B. J., Pham, V., Holien, J. K., Parker, M. W., Thompson, P. E., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01402.x · Cited by 84
Alzheimer's disease and age-related memory decline (preclinical)
Terry, A. V., Callahan, P. M., Hall, B. J., & Webster, S. J. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.02.002 · Cited by 86
Sharma, R., Rahi, S., & Mehan, S. (2019) · Toxicology Reports · doi:10.1016/j.toxrep.2019.10.019 · Cited by 80
Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex
Lee, J. H., Agacinski, G., Williams, J. H., Wilcock, G. K., Esiri, M. M., Francis, P. T., Wong, P. T. ‐., Chen, C., & Lai, M. K. P. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.10.010 · Cited by 76
Is it possible to improve neurodevelopmental abnormalities in Down syndrome?
Bartesaghi, R., Guidi, S., & Ciani, E. (2011) · Reviews in the Neurosciences · doi:10.1515/rns.2011.037 · Cited by 77
Classics in Chemical Neuroscience: Memantine
Alam, S., Lingenfelter, K. S., Bender, A. M., & Lindsley, C. W. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00270 · Cited by 75
Molino, I., Colucci, L., Fasanaro, A. M., Traini, E., & Amenta, F. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/925702 · Cited by 73
Kumar, A., Dejanovic, B., Hetsch, F., Semtner, M., Fuscà, D., Arjune, S., Santamaria‐Araujo, J. A., Winkelmann, A., Ayton, S., Bush, A. I., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89885 · Cited by 70
Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases
Erster, O., Thomas, J. M., Hamzah, J., Jabaiah, A. M., Getz, J. A., Schoep, T. D., Hall, S. S., Ruoslahti, E. I., & Daugherty, P. S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.035 · Cited by 70
Use of memantine for the treatment of dementia
Lo, D. T., & Grossberg, G. T. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.132 · Cited by 71
Clinical Guidelines for Cognitive Disorders in Elderly and Older Patients
Bogolepova, A. N., Васенина, Е. Е., Gomzyakova, N. A., Gusev, E. I., Dudchenko, N. G., Emelin, А. Y., Zalutskaya, N. M., Isaev, R. I., Kotovskaya, Y. V., Levin, O. S., et al. (2021) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20211211036 · Cited by 72
Memantine in dementia: a review of the current evidence
Herrmann, N., Li, A., & Lanctôt, K. L. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.558006 · Cited by 71
Microglia-inhibiting activity of Parkinson's disease drug amantadine
Kim, J., Lee, H., Hwang, J., Kim, J., Lee, M.-J., Han, H. S., Lee, W., & Suk, K. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.08.011 · Cited by 61
Control of Intracellular Calcium Signaling as a Neuroprotective Strategy
Duncan, R. S., Goad, D. L., Grillo, M. A., Kaja, S., Payne, A. J., & Koulen, P. (2010) · Molecules · doi:10.3390/molecules15031168 · Cited by 59
Stubendorff, K., Larsson, V., Ballard, C. G., Minthon, L., Aarsland, D., & Londos, E. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005158 · Cited by 58
Ghosh, S., Durgvanshi, S., Agarwal, S., Raghunath, M., & Sinha, J. K. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200429011823 · Cited by 57
Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before
Mancuso, C., Siciliano, R., Barone, E., Butterfield, D. A., & Preziosi, P. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.601740 · Cited by 53
Filali, M., Lalonde, R., & Rivest, S. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.035 · Cited by 55
Wright, J. W., Kawas, L. H., & Harding, J. W. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.11.004 · Cited by 51
Memantine for Fragile X–Associated Tremor/Ataxia Syndrome
Seritan, A. L., Nguyen, D. V., Mu, Y., Tassone, F., Bourgeois, J. A., Schneider, A., Cogswell, J. B., Cook, K., Leehey, M. A., Grigsby, J., et al. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08546 · Cited by 53
Lebois, E. P., Schroeder, J. P., Esparza, T. J., Bridges, T. M., Lindsley, C. W., Conn, P. J., Brody, D. L., Daniels, J. S., & Levey, A. I. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00278 · Cited by 45
Memantine: a review of possible uses in child and adolescent psychiatry.
Hosenbocus, S., & Chahal, R. (2013) · Europe PMC (PubMed Central) · Cited by 45
Copenhaver, P. F., Anekonda, T. S., Musashe, D. T., Robinson, K. M., Ramaker, J. M., Swanson, T. L., Wadsworth, T. L., Kretzschmar, D., Woltjer, R. L., & Quinn, J. F. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.006841 · Cited by 44
Memantine, a promising drug for the prevention of neuropathic pain in rat
Morel, V., Etienne, M., Wattiez, A., Dupuis, A., Privat, A.-M., Chalus, M., Eschalier, A., Daulhac, L., & Pickering, G. P. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.06.020 · Cited by 44
Borre, Y. E., Panagaki, T., Koelink, P. J., Morgan, M. E., Hendriksen, H., Garssen, J., Kraneveld, A. D., Olivier, B., & Oosting, R. S. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.11.009 · Cited by 42
Bent‐Ennakhil, N., Coste, F., Xie, L., Aigbogun, M. S., Wang, Y., Kariburyo, F., Hartry, A., Başer, O., Neumann, P. J., & Fillit, H. M. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0067-7 · Cited by 42
Hunter, S., Arendt, T., & Brayne, C. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8445-3 · Cited by 41
Arbutin attenuates monosodium L-glutamate induced neurotoxicity and cognitive dysfunction in rats
Kumar, M., Kumar, A., Sindhu, R. K., & Kushwah, A. S. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105217 · Cited by 41
Wright, J. W., & Harding, J. W. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142814 · Cited by 40
Memantine for the treatment of general neuropathic pain: a narrative review
Pickering, G. P., & Morel, V. (2017) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12316 · Cited by 41
Kazemeini, S., Nadeem-Tariq, A., Shih, R., Rafanan, J., Ghani, N., & Vida, T. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111720 · Cited by 41
When Patient Engagement and Research Ethics Collide: Lessons from a Dementia Forum
Robillard, J. M., & Feng, T. L. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161285 · Cited by 38
Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease
Bassil, N., Thaipisuttikul, P., & Grossberg, G. T. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.493874 · Cited by 38
Fessel, J. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.09.019 · Cited by 37
Фу, Л., Kwok, S. S., Chan, Y. K., Lai, J. S. M., Pan, W., Nie, L., & Shih, K. C. (2019) · BioMed Research International · doi:10.1155/2019/8397521 · Cited by 35
Memantine for autism spectrum disorder
Brignell, A., Marraffa, C., Williams, K. J., & May, T. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013845.pub2 · Cited by 36
Reversal of Calcium Dysregulation as Potential Approach for Treating Alzheimer's Disease
Александровна, П. Е., Chernyuk, D., & Борисович, Б. И. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200528162046 · Cited by 34
Memantine and reduced time with dyskinesia in Parkinson′s Disease
Wictorin, K., & Widner, H. (2015) · Acta Neurologica Scandinavica · doi:10.1111/ane.12468 · Cited by 32
MacLean, M. A., Muradov, J. H., Greene, R., van Hameren, G., Clarke, D. B., Dreier, J. P., Okonkwo, D. O., & Friedman, A. (2023) · Science Advances · doi:10.1126/sciadv.adj2417 · Cited by 33
Cognitive effects of modafinil in patients with multiple sclerosis: A clinical trial.
Ford-Johnson, L., DeLuca, J., Zhang, J., Elovic, E. P., Lengenfelder, J., & Chiaravalloti, N. D. (2015) · Rehabilitation Psychology · doi:10.1037/a0039919 · Cited by 32
Bhattacharjee, S., Patanwala, A. E., Lo‐Ciganic, W., Malone, D. C., Lee, J. K., Knapp, S. M., Warholak, T. L., & Burke, W. J. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.005 · Cited by 30
Treatment of cognitive impairment in patients with multiple sclerosis
Patti, F. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.716036 · Cited by 31
Manning, S. M., Boll, G., Fitzgerald, E. F., Selip, D. B., Volpe, J. J., & Jensen, F. E. (2011) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2011.05.005 · Cited by 29
Александровна, П. В., Chernyuk, D., Sysoev, Y. I., Zernov, N., Okovityi, S. V., & Александровна, П. Е. (2020) · Cells · doi:10.3390/cells9112351 · Cited by 29
Memantine as an Augmentation Therapy for Anxiety Disorders
Schwartz, T. L., Siddiqui, U. A., & Raza, S. (2012) · Case Reports in Psychiatry · doi:10.1155/2012/749796 · Cited by 27
Lowinus, T., Bose, T., Busse, S., Busse, M., Reinhold, D., Schraven, B. L., & Bommhardt, U. (2016) · Oncotarget · doi:10.18632/oncotarget.10777 · Cited by 27
The Transcription Factor XBP1 in Memory and Cognition: implications in Alzheimer’s Disease
Cissé, M., Duplan, E., & Checler, F. (2016) · Molecular Medicine · doi:10.2119/molmed.2016.00229 · Cited by 28
Duggal, P., & Mehan, S. (2019) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190125 · Cited by 28
Jafari, A., Ghasemnejad‐Berenji, H., Nemati, M., Pashapour, S., Sadeghpour, S., & Ghasemnejad‐Berenji, M. (2021) · Journal of Pediatric Urology · doi:10.1016/j.jpurol.2021.04.014 · Cited by 26
Holthoff‐Detto, V., Ferris, S. H., Ihl, R., Robert, P. H., Winblad, B. G., Gauthier, S. G., Sternberg, K., & Tennigkeit, F. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt89 · Cited by 26
Mechanisms and the clinical relevance of complex drug–drug interactions
Roberts, A. G., & Gibbs, M. E. (2018) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s146115 · Cited by 26
Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment
Johansson, C., Ballard, C. G., Hansson, O., Palmqvist, S., Minthon, L., Aarsland, D., & Londos, E. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2516 · Cited by 26
Brain α2δ-1–Bound NMDA Receptors Drive Calcineurin Inhibitor–Induced Hypertension
Zhou, J., Shao, J.-Y., Chen, S., & Pan, H. (2023) · Circulation Research · doi:10.1161/circresaha.123.322562 · Cited by 25
New perspective to develop memantine orally disintegrating tablet formulations: SeDeM expert system
Pınar, S. G., Usta, D. Y., Gülteki̇n, H. E., Oktay, A. N., Demirtaş, Ö., Karaküçük, A., & Çelebi, N. (2017) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2017.1345941 · Cited by 24
Inoue, Y., Ueda, M., Masuda, T., Misumi, Y., Yamashita, T., & Ando, Y. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01678-7 · Cited by 25
Moschovos, C., Kostopoulos, G., & Papatheodoropoulos, C. (2012) · Epilepsy Research · doi:10.1016/j.eplepsyres.2012.02.012 · Cited by 24
Matsuoka, T., Narumoto, J., Shibata, K., Okamura, A., Taniguchi, S., Kitabayashi, Y., & Fukui, K. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/245091 · Cited by 24
Drug-Drug Interactions in Prostate Cancer Treatment
Hebenstreit, D., Pichler, R., & Heidegger, I. M. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.05.016 · Cited by 23
Memantine and its benefits for cancer, cardiovascular and neurological disorders
Shafiei‐Irannejad, V., Abbaszadeh, S., Janssen, P. M. L., & Soraya, H. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174455 · Cited by 23
Marimuthu, P., Varadarajan, S., Krishnan, M., Shanmugam, S., Kunjuraman, G., Ravinder, J. R., Balasubramanian, A., Alex, D., & Swaminathan, P. (2016) · Annals of Indian Academy of Neurology · doi:10.4103/0972-2327.179971 · Cited by 23
Cardioprotective effects of memantine in myocardial ischemia: Ex vivo and in vivo studies
Jannesar, K., Abbaszadeh, S., Malekinejad, H., & Soraya, H. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173277 · Cited by 22
Anoush, M., Pourmansouri, Z., Javadi, R., GhorbanPour, B., Sharafi, A., Mohamadpour, H., Anarkooli, I. J., & Andalib, S. (2022) · ACS Omega · doi:10.1021/acsomega.2c00231 · Cited by 21
Effect of Memantine on Cough Reflex Sensitivity: Translational Studies in Guinea Pigs and Humans
Dicpinigaitis, P. V., Canning, B. J., Garner, R. M., & Paterson, B. M. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.221218 · Cited by 21
Cognitive ‘Omics’: Pattern-Based Validation of Potential Drug Targets
Gyertyán, I. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.010 · Cited by 20
Paez, J. A., & Campillo, N. E. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180226095132 · Cited by 20
Clinical guidelines «Cognitive disorders in the elderly and senile persons»
Tkacheva, O. N., Yahno, N. N., Незнанов, Н. Г., Шпорт, С. В., Shamalov, N. A., Levin, O. S., Kostyuk, G. P., Gusev, E. I., Martynov, M. Y., Si, G., et al. (2025) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2025125337 · Cited by 22
Role of Neuronal TRPC6 Channels in Synapse Development, Memory Formation and Animal Behavior
Zernov, N., & Александровна, П. Е. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015415 · Cited by 18
Lazzeroni, L. C., Halbauer, J. D., Ashford, J. W., Noda, A. M., Hernandez, B., Azor, V., Hozack, N. E., Hasson, N. K., Henderson, V. W., Yesavage, J. A., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130662 · Cited by 17
Memantine in the Prevention of Radiation-Induced Brain Damage: A Narrative Review
Scampoli, C., Cammelli, S., Galietta, E., SIEPE, G., Buwenge, M., Macchia, G., Deodato, F., Cilla, S., Strigari, L., Chiesa, S., et al. (2022) · Cancers · doi:10.3390/cancers14112736 · Cited by 17
Muszalska, I., Sobczak, A., Kiaszewicz, I., Rabiega, K., Lesniewska, M. A., & Jelińska, A. (2015) · Journal of Analytical Chemistry · doi:10.1134/s1061934815030120 · Cited by 15
An Approach to the Patient with Cognitive Impairment: Delirium and Dementia
Caplan, J. P., & Rabinowitz, T. (2010) · Medical Clinics of North America · doi:10.1016/j.mcna.2010.08.004 · Cited by 15
Rajdev, K., & Mehan, S. (2019) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527318666190610101144 · Cited by 15
Applications of Bridgehead Heterocycles in Drug Design and Medicinal Chemistry
Martino, S. D., Amico, P., & Rosa, M. D. (2025) · Topics in Current Chemistry · doi:10.1007/s41061-025-00502-2 · Cited by 18
Two Cases of Loss of Consciousness After Long-Term Memantine Treatment
Savić, A., & Mimica, N. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.01.010 · Cited by 14
Colestock, T., Wallach, J. V., Mansi, M., Filemban, N., Morris, H., Elliott, S. P., Westphal, F., Brandt, S. D., & Adejare, A. (2017) · Drug Testing and Analysis · doi:10.1002/dta.2213 · Cited by 14
Arshad, A. S. M., Chear, N. J., Ezzat, M. O., Hanapi, N. A., Meesala, R., Suhana Arshad, B., Mansor, S. M., & Mordi, M. N. (2019) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2019.127070 · Cited by 14
Ayyalasomayajula, N., & Challa, S. (2017) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1345425 · Cited by 13
Does mismatch negativity have utility for NMDA receptor drug development in depression?
Murphy, N., Lijffijt, M., Ramakrishnan, N., Vo-Le, B., Vo-Le, B., Iqbal, S., Iqbal, T., O'Brien, B., Smith, M. A., Swann, A., et al. (2021) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2020-1685 · Cited by 11
Makarewicz, D., Sulejczak, D., Duszczyk, M., Małek, M., Słomka, M., & Łazarewicz, J. W. (2014) · Folia Neuropathologica · doi:10.5114/fn.2014.45568 · Cited by 12
Acute toxicity, 28-day repeated-dose toxicity and toxicokinetic study of timosaponin BII in rats
Ni, L., Liu, B., Zhang, J., Long, Y., Dong, G., Jin, H., & Ma, B. (2017) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2017.09.021 · Cited by 12
Inflammation During Virus Infection: Swings and Roundabouts
Bhattacharyya, S. (2020) · Springer eBooks · doi:10.1007/978-981-15-1045-8_3 · Cited by 13
Mhillaj, E., Cuomo, V., & Mancuso, C. (2017) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000296 · Cited by 11
Metadata
- Authors
- Grossberg, G., & Thomas, S.
- Affiliations
- Saint Louis University (US)
- Corresponding author
- Grossberg, George
- ORCID
- Grossberg, George
- Venue
- Clinical Interventions in Aging
- Publisher
- Informa UK Limited
- Published
- 2009-09
- Volume
- 4
- Pages
- 367
- ISSN
- 1176-9092 (ISSN-L)
- 1178-1998
- PMC
- PMC2762361
- OpenAlex
- W2008348302
- Cited by
- 151
- References
- 104
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 4 · 2023: 8 · 2022: 7 · 2021: 11 · 2020: 10 · 2019: 12 · 2018: 3 · 2017: 17 · 2016: 6 · 2015: 8 · 2014: 10 · 2013: 10 · 2012: 7
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Interventions in Aging (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- memantine, Alzheimer's disease, dementia, NMDA receptor antagonists, drug safety, drug efficacy, cholinesterase inhibitors, vascular dementia, mild Alzheimer's disease, neuroprotection, neuropsychiatric disorders
- MeSH terms
- Alzheimer Disease, Dementia, Humans, Memantine, Severity of Illness Index, Dopamine Agents, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
